Cadonilimab Efficacy and Safety Meta-Analysis for Gastric Cancer, 182 Patients

182 patients from four clinical studies were analyzed in this meta-analysis. The study pools efficacy and safety outcomes for cadonilimab combined with chemotherapy in gastric or gastroesophageal junction adenocarcinoma, authored by Likun Yang and updated in March 2026. It provides pooled estimates for objective response rate, disease control rate, progression-free survival, and adverse events.

Use Cases

• Benchmarking treatment efficacy based on pooled objective response rate (57%) and disease control rate (97%)
• Assessing safety profiles based on the incidence of grade ≥3 treatment-related adverse events (35%)
• Comparing outcomes across treatment settings using subgroup analysis results for neoadjuvant vs. first-line therapy
• Informing clinical trial design based on the reported median progression-free survival (7.98 months)

Strengths

• Includes data from 182 patients across four clinical studies
• Provides specific pooled estimates with 95% confidence intervals for key efficacy and safety metrics
• Conducted a systematic search across five major databases up to July 2025
• Registered as a systematic review with PROSPERO (CRD420251089855)

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Based on a single-arm meta-analysis of early-phase studies, limiting causal inference

Provenance

Source

Likun Yang via figshare

Collection Method

Systematic search and single-arm meta-analysis of clinical studies from PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov

Time Range

Studies published up to July 20, 2025

Freshness

Last updated 2026-03-17 13:07:22; freshness should be verified

Geography

null